Ibogaine News · Monday, November 9, 2026
Bobby Lee discusses addiction, sobriety, and ibogaine trials
Comedian Bobby Lee opens up about his addiction journey and Texas's ibogaine trials.
Bobby Lee, known for his comedic roles on MADtv and his popular podcasts, recently shared insights into his personal battle with addiction and his journey to sobriety. In an episode of "Ask Dr. Drew" aired on November 9, 2026, Lee discussed his early struggles with meth and heroin, his relapses, and his current state of sobriety. This conversation coincides with the upcoming premiere of his first hour-long stand-up special on Hulu, "Bobby Lee: Finally," set to air on November 27.
Bobby Lee's addiction journey
According to the episode, Lee began using meth at the age of 12 and heroin by 15. Despite achieving sobriety at 17, he faced relapses, notably after his father's death in 2019. Lee emphasized the importance of prioritizing recovery over his career, a message he continues to share with his audience.
Texas ibogaine trials
The episode also featured Bryan Hubbard, CEO of Americans for Ibogaine, who discussed Texas's $50 million investment in ibogaine trials. These trials aim to explore ibogaine's potential in treating opioid use disorder and other conditions. Hubbard highlighted ongoing research at Stanford University focusing on ibogaine's effects on veterans with traumatic brain injuries.
Why it matters
Lee's candid discussion sheds light on the challenges of addiction and the ongoing journey of recovery, offering hope and insight to those facing similar battles. Meanwhile, the Texas ibogaine trials represent a significant investment in exploring alternative treatments for addiction, potentially offering new avenues for those who have not found success with traditional therapies.
Lee's story and the ibogaine trials underscore the importance of continued research and open dialogue in addressing addiction and mental health issues.
Sources
Reporting based on drdrew.com. Read the original in the Sources section above.
Get the newsletter
Ibogaine news, in your inbox.
Occasional dispatches. No spam.